Welcome to our dedicated page for Galecto news (Ticker: GLTO), a resource for investors and traders seeking the latest updates and insights on Galecto stock.
Galecto, Inc. (NASDAQ: GLTO) is a clinical-stage biopharmaceutical company developing novel therapies for cancer and liver diseases, with a growing focus on hematological malignancies. The GLTO news feed on Stock Titan aggregates company announcements, scientific updates and regulatory disclosures so readers can follow how Galecto’s pipeline and corporate strategy evolve over time.
Recent news emphasizes Galecto’s shift toward blood cancers, highlighted by the acquisition of Damora Therapeutics and the integration of a mutant calreticulin (mutCALR)-driven myeloproliferative neoplasm portfolio. Updates describe progress on DMR-001, an anti-mutCALR monoclonal antibody for essential thrombocythemia and myelofibrosis, and DMR-002, an additional anti-mutCALR antibody. News items also cover GB3226, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia, including preclinical data presentations and plans for first-in-human studies.
Investors and followers of GLTO can use this page to track a range of developments: pipeline milestones such as planned IND submissions, preclinical and early clinical data disclosures, corporate transactions including the Damora acquisition and private placements, and leadership changes like the appointment of new executives with hematology/oncology experience. Financial result releases offer context on Galecto’s operating expenses, research and development priorities and cash runway.
This news archive is useful for anyone monitoring how Galecto executes on its strategy in hematology-oncology and liver disease, from the advancement of DMR-001 and GB3226 to the progress of GB1211 in liver cirrhosis and oncology combinations. Bookmark this GLTO news page to quickly access the latest company press releases and related updates as they are reported.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BOSTON, April 13, 2023 – Galecto, a clinical-stage biotechnology company focusing on treatments for fibrosis and cancer, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19 in Orlando, Florida.
The company is conducting a Phase 2a trial of GB1211, a galectin-3 inhibitor, combined with atezolizumab for treating non-small cell lung cancer (NSCLC). Presenting data suggests that inhibiting galectin-1 and dual inhibition of galectin-1 and galectin-3 could offer new cancer therapies.
During the meeting, the following abstracts will be presented:
- Abstract LB104: Preclinical evaluation of Galectin-1 inhibitor on April 17.
- Abstract LB173: Benefits of blocking both Galectin-1 and Galectin-3 on April 18.
Galecto, Inc. (NASDAQ: GLTO) reported its operating and financial results for the year ended December 31, 2022. The company completed the enrollment of the Phase 2b GALACTIC-1 trial for GB0139 in idiopathic pulmonary fibrosis and has three compounds in Phase 2 clinical trials with positive results reported in 2022. Financially, cash equivalents totaled approximately $66.1 million, providing a runway into the second half of 2024. However, the net loss for the year was $61.6 million, resulting in a loss per share of $(2.43), compared to $(2.05) in the previous year. The company anticipates significant milestones in 2023, including key trial results.
BOSTON, March 02, 2023 – Galecto, a clinical-stage biotechnology company focused on fibrosis and cancer treatments, announced its participation in Oppenheimer’s 33rd Annual Healthcare Conference from March 13-15, 2023. Management will present on March 13 at 9:20 am EST and will be available for one-on-one meetings. A live webcast of the presentation can be accessed through Galecto's Investor website, with a replay available after the event.
Galecto's current clinical programs include four Phase 2 trials targeting idiopathic pulmonary fibrosis, myelofibrosis, liver cirrhosis, and non-small cell lung cancer, utilizing various galectin-3 and LOXL2 inhibitors.
BOSTON, Feb. 1, 2023 (GLOBE NEWSWIRE) -- Galecto, a clinical-stage biotechnology company focused on fibrosis and cancer treatments, will present at the SVB Securities Global Biopharma Conference from February 14-16, 2023. The presentation is scheduled for February 14th at 8:00 AM EST. A live webcast will be available on Galecto's Investor website, along with a replay following the event.
Currently, Galecto is developing small molecule inhibitors targeting galectin-3 and LOXL2, with four ongoing Phase 2 trials including treatments for idiopathic pulmonary fibrosis and non-small cell lung cancer.
FAQ
What is the current stock price of Galecto (GLTO)?
What is the market cap of Galecto (GLTO)?
